Leveraged Commentary and Data’s (LCD) credit data, news, and research are now on PitchBook.
Learn more »
Latest Deal Type
Early Stage VC
BioXpress General Information
Developer of biosimilar monoclonal antibodies (mAbs) designed to address situations like cancer, inflammation and autoimmunity. The company utilizes biosimilar biologic active pharmaceutical ingredients (APIs) to bring speed, efficiency and safety in developing biosimilar mAbs that impact patients' quality of life while maintaining low development costs, enabling doctors to make drugs accessible while also offering to prolong and improve the lives of patients across the globe.